description of the effectiveness, safety, tolerability and adherence to amlodipine/atorvastatin/perindopril single pill combination treatment in patients with arterial hypertension and dyslipidemia (target)

Conditions: Arterial Hypertension; HTN

Summary: this is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with htn and dyslipidemia initiated with spc of amlodipine/atorvastatin/perindopril in real clinical settings. a total of 80 general practitioners and outpatient cardiologists will participate in this non-interventional study 400 patients should be included in the study.

treatment with the studied drug: * amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg * amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg * amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg this is non-interventional study that is observational by its nature. therefore there will be no any assignments of subjects to a particular therapeutic strategies defined by this protocol. decision to treat a patient with spc of amlodipine/ atorvastatin/ perindopril should be at the descretion of a treating investigator and made in accordance to local standards and protocols.

Eligibility criteria:
inclusion criteria: * obtained signed informed consent from the patient * patients of 18 years and older and younger than 80 years. * start of the treatment with spc of amlodipine/atorvastatin/perindopril within 1 month from the index date in accordance with the indication in russian smpc. * presence of the parameters of interest\* in the medical records dated with the nearest to the start of spc amlodipine/atorvastatin/perindopril treatment date. * parameters of interest include measured at rest office bp and ldl-c. exclusion criteria: * subjects who are unwilling or unable to provide a signed informed consent form; * any contraindication to the treatment with the spc of amlodipine/atorvastatin/perindopril according to its' approved instruction for medical use in the russian federation; * concomitant use of any other ace inhibitors, ccbs, arbs and statins. * supposed low treatment adherence to the assigned spc and the risk for poor collaboration between the patient and the investigator during the study; * any severe, decompensated or unstable somatic diseases or states that according to investigator discretion are life-threatening or worsen the prognosis for the patient: myocardial infarction in the past 3 months, unstable angina, current decompensation of diabetes mellitus, autoimmune or oncological diseases, severe cardiac arrhythmia, gastrointestinal disorders affecting absorbtion, severe hepatic diseases, pancreatic diseases, severe allergic reactions, connective tissue diseases etc; * secondary arterial hypertension; * alcohol or any drug abuse; * surgical intervention on heart or coronary vessels (i.e., heart valve(s) replacement, stent implantation or cabg), or any non-cardiological serious surgical intervention that are planned within next 3 months and may require withdrawal or changes in current therapy; * glomerular filtration rate less than 60 ml/min/1,72m2; * participating in any other clinical trial currently or during 30 days period before informed consent was signed.